FluidForm Bio
FluidForm Bio™ is revolutionizing medicine through its patented FRESH™ technology, which enables the bioprinting of living human tissue for advanced cell therapy and disease treatment. Founded in 2018, the company integrates innovations in 3D printing, synthetic biology, and AI to create tissue that closely resembles natural human tissue, aiming to improve patient outcomes and transform healthcare.
FluidForm Bio
What We Do
A revolutionary 3D bioprinting platform that builds living human tissue using cells and proteins, enabling chronic cures and advanced cell therapy applications.
Digital Health Technologies
Key People
Chief Executive Officer & Co-founder
Chief Technology Officer & Co-founder
General Counsel & Head of Corporate Strategy
Chief Marketing Officer
Chief Business Officer
Vice President of People & Business Operations
News & Updates
FluidForm Bio announced the appointment of Jonathan Paris as general counsel and head of corporate strategy, Naomi Phaneuf as chief marketing officer, and Alex Lenz as vice president of people & business operations.
FluidForm Bio shares recent advancements in building human cardiac tissues using FRESH™ 3D bioprinting.
FluidForm’s CDDP is the first tool to provide actionable signals at the critical juncture of lead selection and optimization.